Ningbo MedicalSystem Biotechnology Co Ltd Strategic Asset Allocation Index
Ningbo MedicalSystem Biotechnology Co Ltd strategic asset allocation index. Ningbo MedicalSystem Biotechnology Co Ltd (300439) has a Strategic Asset Allocation Index of 42.3% as of December 2022. Strategic assets (PP&E of CN¥1.07 Billion plus long-term investments of CN¥-) total CN¥1.07 Billion, measured against net assets of CN¥2.52 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Ningbo MedicalSystem Biotechnology Co Lt (300439) net asset quality to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Ningbo MedicalSystem Biotechnology Co Ltd (2012–2022)
Strategic asset allocation index of Ningbo MedicalSystem Biotechnology Co Ltd from 2012 to 2022. This chart shows how Ningbo MedicalSystem Biotechnology Co Ltd's Strategic Asset Allocation Index has evolved across 11 annual periods from 2012 to 2022. As of December 2022, the index stands at 42.3%, representing strategic assets of CN¥1.07 Billion against net assets of CN¥2.52 Billion CNY. Check 300439 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Ningbo MedicalSystem Biotechnology Co Ltd Strategic Asset Allocation Index by Year (2012–2022)
Ningbo MedicalSystem Biotechnology Co Ltd strategic asset allocation index by year from 2012 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Ningbo MedicalSystem Biotechnology Co Ltd from 2012 to 2022, covering 11 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market cap of Ningbo MedicalSystem Biotechnology Co Lt.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 42.3% | CN¥1.07 Billion | CN¥1.07 Billion | CN¥- | CN¥2.52 Billion | ▼ -1.6 pp |
| 2021 | 43.9% | CN¥1.05 Billion | CN¥1.05 Billion | CN¥- | CN¥2.39 Billion | ▼ -18.1 pp |
| 2020 | 62.0% | CN¥1.05 Billion | CN¥1.05 Billion | CN¥- | CN¥1.69 Billion | ▼ -3.3 pp |
| 2019 | 65.3% | CN¥906.21 Million | CN¥906.21 Million | CN¥- | CN¥1.39 Billion | ▲ +21.2 pp |
| 2018 | 44.1% | CN¥1.00 Billion | CN¥721.95 Million | CN¥278.06 Million | CN¥2.27 Billion | ▲ +12.7 pp |
| 2017 | 31.3% | CN¥716.12 Million | CN¥521.80 Million | CN¥194.32 Million | CN¥2.29 Billion | ▲ +1.6 pp |
| 2016 | 29.7% | CN¥543.25 Million | CN¥265.34 Million | CN¥277.91 Million | CN¥1.83 Billion | ▲ +15.7 pp |
| 2015 | 14.0% | CN¥180.56 Million | CN¥180.56 Million | CN¥- | CN¥1.29 Billion | ▼ -21.0 pp |
| 2014 | 35.0% | CN¥145.44 Million | CN¥145.44 Million | CN¥- | CN¥415.13 Million | ▼ -2.0 pp |
| 2013 | 37.1% | CN¥114.29 Million | CN¥114.29 Million | CN¥- | CN¥308.32 Million | ▼ -8.8 pp |
| 2012 | 45.9% | CN¥92.99 Million | CN¥92.99 Million | CN¥- | CN¥202.58 Million | — |